Travoprost-Optik eye drops 0.004%, 5ml

Composition

1 ml. :

Active ingredient: travoprost-0.04 mg; Excipients:

• boric acid – 3,00 mg
• trometamol -1,20 mg,
• macrogol glycerylmonostearate – 5.00 mg,
• mannitol (Mannitol D) of 46.00 mg,
• disodium edetate – 0.10 mg,
• benzalkonium chloride in anhydrous substance – 0.15 mg,1 M hydrochloric acid solution or 1 M solution of sodium hydroxide to a pH of 5.5 to 6.5,
• purified water – up to 1.0 ml.

Pharmacological action

Anti – glaucoma agent-prostaglandin F2-alpha synthetic analog. Travoprost is absorbed through the cornea of the eye, where it is hydrolyzed to a biologically active form – travoprost acid. Cmax of travoprost in blood plasma is reached within 30 minutes after topical application and is 25 pg / ml or less. Travoprost is rapidly eliminated from the plasma, and within an hour the concentration decreases below the detection threshold. Pharmacodynamics

Travoprost, a synthetic analog of prostaglandin F2a, is a highly selective complete agonist of prostaglandin FP receptors and reduces intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork and uveoscleral pathways.

Intraocular pressure decreases approximately 2 hours after application, and the maximum effect is achieved after 12 hours.

A significant decrease in intraocular pressure may persist for 24 hours after a single dose of the drug.

Indications

Reduction of increased intraocular pressure in open-angle glaucoma, increased ophthalmotonus.

Use during pregnancy and lactation

Use during pregnancy is contraindicated.

There is no sufficient experience of using it during lactation.

Use during breastfeeding is possible only under the supervision of a doctor and only if the potential benefit of therapy for the mother exceeds the possible risk of side effects for the infant.

Contraindications

Children and adolescents under 18 years of age, hypersensitivity to travoprost.

Use with caution in the presence of risk factors for the development of macular edema (aphakia, pseudophakia, damage to the posterior lens capsule), in acute iritis, uveitis.

Side effects

From the side of the organ of vision: very often – transient mild conjunctival hyperemia that passes independently; often – decreased visual acuity, discomfort and foreign body sensation, pain, itching, burning in the eyes, visual disorders, blepharitis, “fog” in front of the eyes, cataracts, conjunctivitis, dry conjunctiva, changes in the color of the iris, keratitis, crusting on the edges of the eyelids, photophobia, subconjunctival hemorrhages and increased lacrimation.

From the cardiovascular system: often-increased or decreased blood pressure, bradycardia, angina pectoris, chest pain, hypercholesterolemia.

From the central nervous system: often-general anxiety, headache, depression.

From the urinary system: often – urinary incontinence and infections of the urinary system.

From the musculoskeletal system: often-arthritis, back pain.

Other: often-flu-like syndrome, sinusitis, bronchitis, dyspepsia.

How to take, course of use and dosage

Instill 1 drop in the conjunctival sac of the affected eye (s) 1 time/day, preferably in the evening.

Special instructions

Against the background of the application, a gradual change in eye color is possible due to an increase in the amount of brown pigment in the iris.

This effect is detected mainly in patients with mixed color of the iris, for example, blue-brown, gray-brown, green-brown or yellow-brown, which is explained by an increase in the content of melanin in the stromal melanocytes of the iris.

Usually, brown pigmentation spreads concentrically around the pupil to the periphery of the iris, and the entire iris or parts of it may turn a more intense brown color.

In patients with evenly colored blue, gray, green, or brown eyes, changes in eye color after two years of using the drug were very rare. The color change is not accompanied by any clinical symptoms or pathological changes.

After discontinuation of therapy, there was no further increase in the amount of brown pigment, but the color change that has already developed may be irreversible.

Before starting treatment, patients should be informed about the possibility of changing eye color.

Treating only one eye can lead to permanent heterochromia.

In the presence of nevi or lentigo on the iris, their changes under the influence of travoprost were not noted.

Travoprost can cause darkening, thickening and lengthening of the eyelashes and/or an increase in their number; rarely – darkening of the skin of the eyelids.

It can be used in combination with other topical anti-glaucoma medications. In this case, the interval between their use should be at least 5 minutes.

When wearing contact lenses, the lenses should be removed before instillation and replaced no earlier than 20 minutes after the procedure.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life is 2 years. Keep the opened dropper bottle for no more than 30 days.

Active ingredient

Travoprost

Conditions of release from pharmacies

By prescription

Dosage form

eye drops